MET and glioblastoma: XL-184 (BMS-907351/Cabozantinib) is an oral inhibitor of c-MET, VEGFR-2 and RET,68 and it also has an inhibitory effect on KIT, FLT3 and TEK.69 Initial results from a phase II trial using XL-184 are promising, but further research is required to fully test its efficacy for GBM.68 Other molecules such as Foretinib and SGX-523 inhibit HGFR/c-MET tyrosine kinase and have been shown to reduce tumor growth in vitro and in vivo when using a GBM murine xenograft model.70,71 PD173074 is another multiple tyrosine kinase inhibitor that inhibits FGFR and VEGFR tyrosine kinases.